APG-3288 for Blood Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Who Is on the Research Team?
Keshu Zhou, M.D.,Ph.D.
Principal Investigator
Henan Cancer Hospital
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation Phase
Participants receive orally administered APG-3288 at specified doses once daily in 28-day cycles to determine the MTD or RP2D
Dose Expansion Phase
Further evaluation of dose safety with up to 60 patients per chosen indication enrolled and randomly assigned to dose cohorts
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- APG-3288
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Indications and dose cohorts to be determined from Part 1
APG-3288 at multiple dose levels will be evaluated to determine the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ascentage Pharma Group Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.